FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2136054802> ?p ?o ?g. }

• W2136054802 endingPage "1436" @default.
• W2136054802 startingPage "1429" @default.
• W2136054802 abstract "Treatment with statins reduces the rate of cardiovascular events in high-risk patients, but residual risk persists. At least part of that risk may be attributable to atherogenic dyslipidemia characterized by low high-density lipoprotein cholesterol (≤40 mg/dL) and high triglycerides (triglycerides≥150 mg/dL).We studied subjects with stroke or transient ischemic attack in the Prevention of Cerebrovascular and Cardiovascular Events of Ischemic Origin With Terutroban in Patients With a History of Ischemic Stroke or Transient Ischemic Attack (PERFORM; n=19,100) and Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL; n=4731) trials who were treated with a statin and who had high-density lipoprotein cholesterol and triglycerides measurements 3 months after randomization (n=10,498 and 2900, respectively). The primary outcome measure for this exploratory analysis was the occurrence of major cardiovascular events (nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death). We also performed a time-varying analysis to account for all available high-density lipoprotein cholesterol and triglyceride measurements.A total of 10% of subjects in PERFORM and 9% in SPARCL had atherogenic dyslipidemia after ≥3 months on start statin therapy. After a follow-up of 2.3 years (PERFORM) and 4.9 years (SPARCL), a major cardiovascular event occurred in 1123 and 485 patients in the 2 trials, respectively. The risk of major cardiovascular events was higher in subjects with versus those without atherogenic dyslipidemia in both PERFORM (hazard ratio, 1.36; 95% confidence interval, 1.14-1.63) and SPARCL (hazard ratio, 1.40; 95% confidence interval, 1.06-1.85). The association was attenuated after multivariable adjustment (hazard ratio, 1.23; 95% confidence interval, 1.03-1.48 in PERFORM and hazard ratio, 1.24; 95% confidence interval, 0.93-1.65 in SPARCL). Time-varying analysis confirmed these findings.The presence of atherogenic dyslipidemia was associated with higher residual cardiovascular risk in PERFORM and SPARCL subjects with stroke or transient ischemic attack receiving statin therapy. Specific therapeutic interventions should now be trialed to address this residual risk." @default.
• W2136054802 created "2016-06-24" @default.
• W2136054802 creator A5000039714 @default.
• W2136054802 creator A5001628967 @default.
• W2136054802 creator A5007737202 @default.
• W2136054802 creator A5012768332 @default.
• W2136054802 creator A5013990412 @default.
• W2136054802 creator A5015845166 @default.
• W2136054802 creator A5016095791 @default.
• W2136054802 creator A5018531683 @default.
• W2136054802 creator A5020503013 @default.
• W2136054802 creator A5023091399 @default.
• W2136054802 creator A5028934169 @default.
• W2136054802 creator A5031132136 @default.
• W2136054802 creator A5034280171 @default.
• W2136054802 creator A5036747513 @default.
• W2136054802 creator A5055596681 @default.
• W2136054802 creator A5057843713 @default.
• W2136054802 creator A5063827105 @default.
• W2136054802 date "2014-05-01" @default.
• W2136054802 modified "2023-10-12" @default.
• W2136054802 title "Atherogenic Dyslipidemia and Residual Cardiovascular Risk in Statin-Treated Patients" @default.
• W2136054802 cites W1519335354 @default.
• W2136054802 cites W1546258268 @default.
• W2136054802 cites W155654176 @default.
• W2136054802 cites W1973860866 @default.
• W2136054802 cites W1976428272 @default.
• W2136054802 cites W1981197903 @default.
• W2136054802 cites W1991436488 @default.
• W2136054802 cites W1992909865 @default.
• W2136054802 cites W1997531859 @default.
• W2136054802 cites W1998346188 @default.
• W2136054802 cites W2004353849 @default.
• W2136054802 cites W2011985302 @default.
• W2136054802 cites W2030551858 @default.
• W2136054802 cites W2031020688 @default.
• W2136054802 cites W2046183081 @default.
• W2136054802 cites W2064707131 @default.
• W2136054802 cites W2071048602 @default.
• W2136054802 cites W2071298734 @default.
• W2136054802 cites W2074866078 @default.
• W2136054802 cites W2094124359 @default.
• W2136054802 cites W2094768566 @default.
• W2136054802 cites W2096210401 @default.
• W2136054802 cites W2098690816 @default.
• W2136054802 cites W2102691551 @default.
• W2136054802 cites W2106685042 @default.
• W2136054802 cites W2117541022 @default.
• W2136054802 cites W2117641691 @default.
• W2136054802 cites W2121145204 @default.
• W2136054802 cites W2125763086 @default.
• W2136054802 cites W2138467463 @default.
• W2136054802 cites W2139168645 @default.
• W2136054802 cites W2144251666 @default.
• W2136054802 cites W2144516660 @default.
• W2136054802 cites W2149433053 @default.
• W2136054802 cites W2151865549 @default.
• W2136054802 cites W2155121555 @default.
• W2136054802 cites W2160081172 @default.
• W2136054802 cites W2164324917 @default.
• W2136054802 cites W2170100458 @default.
• W2136054802 cites W2198678228 @default.
• W2136054802 cites W4232807629 @default.
• W2136054802 doi "https://doi.org/10.1161/strokeaha.113.004229" @default.
• W2136054802 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24736236" @default.
• W2136054802 hasPublicationYear "2014" @default.
• W2136054802 type Work @default.
• W2136054802 sameAs 2136054802 @default.
• W2136054802 citedByCount "67" @default.
• W2136054802 countsByYear W21360548022014 @default.
• W2136054802 countsByYear W21360548022015 @default.
• W2136054802 countsByYear W21360548022016 @default.
• W2136054802 countsByYear W21360548022017 @default.
• W2136054802 countsByYear W21360548022018 @default.
• W2136054802 countsByYear W21360548022019 @default.
• W2136054802 countsByYear W21360548022020 @default.
• W2136054802 countsByYear W21360548022021 @default.
• W2136054802 countsByYear W21360548022022 @default.
• W2136054802 countsByYear W21360548022023 @default.
• W2136054802 crossrefType "journal-article" @default.
• W2136054802 hasAuthorship W2136054802A5000039714 @default.
• W2136054802 hasAuthorship W2136054802A5001628967 @default.
• W2136054802 hasAuthorship W2136054802A5007737202 @default.
• W2136054802 hasAuthorship W2136054802A5012768332 @default.
• W2136054802 hasAuthorship W2136054802A5013990412 @default.
• W2136054802 hasAuthorship W2136054802A5015845166 @default.
• W2136054802 hasAuthorship W2136054802A5016095791 @default.
• W2136054802 hasAuthorship W2136054802A5018531683 @default.
• W2136054802 hasAuthorship W2136054802A5020503013 @default.
• W2136054802 hasAuthorship W2136054802A5023091399 @default.
• W2136054802 hasAuthorship W2136054802A5028934169 @default.
• W2136054802 hasAuthorship W2136054802A5031132136 @default.
• W2136054802 hasAuthorship W2136054802A5034280171 @default.
• W2136054802 hasAuthorship W2136054802A5036747513 @default.
• W2136054802 hasAuthorship W2136054802A5055596681 @default.
• W2136054802 hasAuthorship W2136054802A5057843713 @default.
• W2136054802 hasAuthorship W2136054802A5063827105 @default.
• W2136054802 hasBestOaLocation W21360548021 @default.

• next